Literature DB >> 17522198

Rates of reactivation of latent herpes simplex virus from mouse trigeminal ganglia ex vivo correlate directly with viral load and inversely with number of infiltrating CD8+ T cells.

Yo Hoshino1, Lesley Pesnicak, Jeffrey I Cohen, Stephen E Straus.   

Abstract

Herpes simplex viruses (HSV) reactivate at rates proportional to the viral loads in latently infected ganglia. However, these rates vary substantially among infected animals. We assessed whether the numbers of HSV-specific CD8(+) T cells infiltrating latently infected ganglia also affect reactivation rates and contribute to their variability. Following corneal infection of mice with HSV type 2 (HSV-2), we quantified the latent viral loads in dissociated trigeminal ganglia by real-time PCR, the numbers of infiltrating CD8(+) T cells by flow cytometry, and the rates of reactivation by the detection of cell-free virus released from ganglion cells cultured in 96-well plates. The reactivation rates correlated directly with the latent viral loads (P = 0.001) but did so more strongly (P = 10(-7)) when cultures were depleted of CD8(+) T cells. Reactivation rates were reduced in a dose-dependent fashion by adding back ganglion CD8(+) T cells to the cultures (P = 0.003). We related the latent viral loads, numbers of CD8(+) T cells, and reactivation rates by mathematical equations. The rates of reactivation predicted from latent viral loads and numbers of infiltrating CD8(+) T cells in dissociated ganglia correlated with the observed rates of reactivation (P = 0.04). The reactivation of HSV-2 from ganglia ex vivo is determined both by the latent viral load and the number of infiltrating CD8(+) T cells.

Entities:  

Mesh:

Year:  2007        PMID: 17522198      PMCID: PMC1951330          DOI: 10.1128/JVI.00474-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Authors:  Yo Hoshino; Sarat K Dalai; Kening Wang; Lesley Pesnicak; Tsz Y Lau; David M Knipe; Jeffrey I Cohen; Stephen E Straus
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects.

Authors:  Guy de Bruyn; Mauricio Vargas-Cortez; Terri Warren; Stephen K Tyring; Kenneth H Fife; Jacob Lalezari; Rebecca C Brady; Mohsen Shahmanesh; George Kinghorn; Karl R Beutner; Rajul Patel; Margaret A Drehobl; Patrick Horner; Terrance O Kurtz; Sharon McDermott; Anna Wald; Lawrence Corey
Journal:  Vaccine       Date:  2005-09-21       Impact factor: 3.641

3.  Latent infection with herpes simplex virus is associated with ongoing CD8+ T-cell stimulation by parenchymal cells within sensory ganglia.

Authors:  Allison L van Lint; Lauren Kleinert; Sally R M Clarke; Angus Stock; William R Heath; Francis R Carbone
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.

Authors:  M Wachsman; M Kulka; C C Smith; L Aurelian
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

5.  The 2.2-kilobase latency-associated transcript of herpes simplex virus type 2 does not modulate viral replication, reactivation, or establishment of latency in transgenic mice.

Authors:  K Wang; L Pesnicak; E Guancial; P R Krause; S E Straus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation.

Authors:  S H Chen; D A Garber; P A Schaffer; D M Knipe; D M Coen
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

7.  Gamma interferon impedes the establishment of herpes simplex virus type 1 latent infection but has no impact on its maintenance or reactivation in mice.

Authors:  J A Lekstrom-Himes; R A LeBlanc; L Pesnicak; M Godleski; S E Straus
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; B N Carriere; R L Hendricks
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Persistent expression of chemokine and chemokine receptor RNAs at primary and latent sites of herpes simplex virus 1 infection.

Authors:  W James Cook; Martha F Kramer; Russell M Walker; Timothy J Burwell; Holly A Holman; Donald M Coen; David M Knipe
Journal:  Virol J       Date:  2004-09-23       Impact factor: 4.099

10.  CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; X Chen; D J Fink; R L Hendricks
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

View more
  61 in total

Review 1.  CD8+ T cells patrol HSV-1-infected trigeminal ganglia and prevent viral reactivation.

Authors:  Anthony J St Leger; Robert L Hendricks
Journal:  J Neurovirol       Date:  2011-12-08       Impact factor: 2.643

2.  The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia.

Authors:  Yo Hoshino; Jing Qin; Dean Follmann; Jeffrey I Cohen; Stephen E Straus
Journal:  Virology       Date:  2007-11-28       Impact factor: 3.616

3.  PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia.

Authors:  Sohyun Jeon; Anthony J St Leger; Thomas L Cherpes; Brian S Sheridan; Robert L Hendricks
Journal:  J Immunol       Date:  2013-05-08       Impact factor: 5.422

4.  T cell response kinetics determines neuroinfection outcomes during murine HSV infection.

Authors:  Aisha G Lee; Jason M Scott; Maria Rita Fabbrizi; Xiaoping Jiang; Dorothy K Sojka; Mark J Miller; Megan T Baldridge; Wayne M Yokoyama; Haina Shin
Journal:  JCI Insight       Date:  2020-03-12

Review 5.  Chemokine-mediated immune responses in the female genital tract mucosa.

Authors:  Maud Deruaz; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2015-03-17       Impact factor: 5.126

6.  C21orf91 genotypes correlate with herpes simplex labialis (cold sore) frequency: description of a cold sore susceptibility gene.

Authors:  John D Kriesel; Brandt B Jones; Nori Matsunami; Milan K Patel; Christine A St Pierre; Evelyn A Kurt-Jones; Robert W Finberg; Mark Leppert; Maurine R Hobbs
Journal:  J Infect Dis       Date:  2011-12-01       Impact factor: 5.226

Review 7.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

8.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

9.  Herpesvirus Infections and Risk of Frailty and Mortality in Older Women: Women's Health and Aging Studies.

Authors:  George C Wang; Christina Han; Barbara Detrick; Vincenzo Casolaro; David M Levine; Linda P Fried; Jeremy D Walston
Journal:  J Am Geriatr Soc       Date:  2016-04-30       Impact factor: 5.562

10.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.